Guest Contributor
November 3, 2000

CryoCath Technologies Inc has raised $40 million with an initial public offering (IPO) of eight million shares, the largest life sciences IPO in Canadian history. The Montreal-based developer of catheter cryotherapy systems for the treatment of cardiovascular disease will use most of the proceeds to complete clinical trials and the regulatory process for its lead product, aimed at the treatment of irregular heartbeats. CryoCath was formed in 1995 based on technology transfer from a Boston-based firm and $2.5 million in seed investments from the backing of BioCapital Investments, Innovatech du grand Montréal and Fonds de solidarité des travailleurs du Québec. Further syndicated private placement followed amounting to $22.6 million and $28.2 million.

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.